ERBB2 and cancer: The HER2+ EV‐mediated decoy effect may lead to the attenuation of the direct cancer growth inhibitory effect of trastuzumab and the ADCC‐related cytotoxic effect of trastuzumab (Battke et al., 2011; Ciravolo et al., 2012).